Ipamorelin

Fitness

Also known as: NNC-26-0161, Ipamorelin Acetate

Emerging Research

What is Ipamorelin?

A synthetic pentapeptide (5 amino acids) developed by Novo Nordisk and first characterised by Raun et al. in 1998. Ipamorelin selectively stimulates growth hormone release from the pituitary gland without meaningfully raising cortisol, prolactin, or ACTH — a selectivity profile that distinguishes it from every earlier GHRP and makes it the most widely studied and most clinically preferred member of the GHRP class. It is most commonly stacked with CJC-1295, which operates through a complementary receptor pathway to extend and amplify the GH pulse.

US regulatory status

Partly restrictedNot FDA-approvedWADA prohibited

Ipamorelin acetate is on the FDA's Category 2 list for 503B outsourcing facilities (added September 29, 2023). The FDA table does not list it for 503A pharmacies, but it is not on the 503A bulks list either, so pharmacy availability varies. Not FDA-approved.

Checked 2026-10-18. Regulatory status changes often — verify before acting. FDA: Category 2 bulk drug substances

How it works

Ipamorelin is an agonist of the ghrelin receptor (GHS-R1a) on somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signalling through the Gq/phospholipase C pathway — releasing IP3 and mobilising intracellular calcium — which causes the pituitary to release stored growth hormone in a discrete pulse. The GH peak occurs at approximately 40 minutes post-administration and returns to baseline within 3 hours, mimicking the natural episodic pattern of GH secretion rather than producing tonic (continuous) elevation. The defining pharmacological feature, established in the original 1998 characterisation, is selectivity: at GH-releasing doses, ipamorelin does not meaningfully elevate ACTH, cortisol, prolactin, FSH, LH, or TSH. GHRP-6 produces significant co-elevation of cortisol and appetite-stimulating ghrelin-like effects; GHRP-2 and hexarelin raise ACTH and cortisol through non-GHS-R1a pathways. Ipamorelin avoids these because its binding is more selective for the GHS-R1a site. The downstream GH axis follows: GHS-R1a activation → pulsatile GH release from pituitary → hepatic IGF-1 synthesis → peripheral IGF-1 receptor signalling.

What marketers claim

▸completely side-effect-free growth hormone optimisation
▸produces the same effects as exogenous HGH injections without the risks
▸clinically proven for anti-aging and body composition
▸approved and legally available through compounding pharmacies
▸optimal GH stimulation when combined with CJC-1295

What evidence supports

✓selective GHS-R1a agonism with a cleaner hormonal profile than GHRP-2 and GHRP-6 is well-established in preclinical research (Raun et al., 1998, 400+ citations)
✓human pharmacokinetic and pharmacodynamic data confirming GH stimulation without significant cortisol or ACTH elevation (Gobburu et al., 1999)
✓Phase 2 randomised controlled trial (n=87) for postoperative ileus in bowel resection — the most rigorous published human study
✓preclinical bone density, body composition, and aged-model GH restoration studies are consistent and reasonably well-replicated
✓150+ PubMed publications as of April 2026 — the most extensively researched of the GHRPs
✓no published human RCT data for body composition, recovery, or anti-aging endpoints

Research evidence

Key studies on Ipamorelin, summarized in plain language. This is not an exhaustive list — it highlights the most relevant findings.

Raun et al. (1998) — original ipamorelin characterisation

1998Animal Study

Finding: Original characterisation of ipamorelin as the first selective GH secretagogue. Demonstrated GH stimulation in swine without significant ACTH, cortisol, or prolactin elevation — directly contrasting the profile of GHRP-2 and GHRP-6. Established the selectivity profile that defines the compound. PMID: 9849822.

Limitation: Swine model. Human translation of the selectivity advantage has been supported by subsequent PK studies but not confirmed in long-term human trials.

Gobburu et al. (1999) — human pharmacokinetic and pharmacodynamic study

1999Clinical Trial

Finding: Human study confirming ipamorelin's GH stimulation profile in human volunteers. Documented the ~40-minute GH peak and return to baseline by 3 hours, confirming pulsatile rather than tonic GH elevation in humans. PMID: 10496658.

Limitation: Short-duration PK/PD study design — does not assess downstream IGF-1 effects, body composition, or long-term outcomes.

Beck et al. (2014) — Phase 2 RCT for postoperative ileus

2014Randomized Controlled Trialn = 87

Finding: Phase 2 randomised controlled trial evaluating ipamorelin for postoperative ileus following bowel resection. Showed tolerability and supported the GH-stimulatory mechanism in a clinical population. PMID: 25331030.

Limitation: The indication (postoperative ileus) is distinct from the body composition and recovery uses for which ipamorelin is most commonly pursued. Results do not directly validate those applications.

Svensson et al. (2000) — preclinical bone density study

2000Animal Study

Finding: Preclinical study in young female rats demonstrating ipamorelin's effects on bone parameters over 8 weeks, including increased bone mineral content and periosteal bone formation. PMID: 10820804.

Limitation: Animal model. Bone effects in humans via GH secretagogue-mediated IGF-1 elevation have not been confirmed in controlled trials for ipamorelin specifically.

Best for

investigational GH axis optimisation in adults seeking to restore youthful GH pulsatility for recovery, sleep quality, and body composition — in a research context with physician oversight; Sermorelin has a longer clinical history as an alternative for similar goals

What to expect

Realistic timeline based on available research. Individual results vary.

Minutes 30–40

GH pulse peaks approximately 40 minutes post-administration in human pharmacokinetic data. Returns to baseline by 3 hours. Measurable via GH serum test timed appropriately post-dose.

Week 1–4

Sleep quality changes are often the earliest reported subjective effect, particularly deeper slow-wave sleep. This is consistent with the GH/sleep relationship — GH is predominantly secreted during slow-wave sleep, and optimising the GH axis tends to show up in sleep quality before visible body composition changes.

Month 1–3

The IGF-1 elevation that underlies body composition effects accumulates over sustained GH pulsatility. Preclinical bone and body composition studies typically use 8-week minimum protocols. Human body composition changes (if they occur) are expected to become measurable in this window.

Month 3+

No controlled human long-term data exists. Practitioners using extended protocols typically cycle 8–12 weeks on, 4–8 weeks off, based on preclinical pulsatility data — sustained tonic GH elevation is associated with receptor downregulation, and the cycling protocol attempts to preserve pulsatile responsiveness.

Safety notes & concerns

Full safety guide →

⚠most common adverse effects in human studies: transient facial flushing, mild headache — both typically resolved within 30 minutes of administration
⚠listed on the FDA's Category 2 list for 503B outsourcing facilities since September 2023; the FDA table does not list it for 503A pharmacies, but it is not on the 503A bulks list either, so availability through pharmacies varies — confirm with a pharmacist
⚠WADA prohibited under peptide hormones and growth factors — competitive athletes face disqualification
⚠no long-term human safety data — most human studies are short-duration PK/PD trials
⚠individuals with active cancer or history of malignancy should not use GH secretagogues — IGF-1 elevation is theoretically concerning in oncology contexts

Pairs well with

CJC-1295 (the most common and mechanistically logical stack — CJC-1295 is a GHRH analog acting at a different receptor that extends GH pulse amplitude and duration; the two peptides act through complementary pathways that are synergistic)adequate sleep (GH is predominantly released during slow-wave sleep — ipamorelin's pulsatile effects are most productive when sleep quality supports the natural GH secretion environment)resistance training (IGF-1 signalling works synergistically with mechanical loading for lean mass and recovery outcomes)

Use caution with

active or historical cancer (IGF-1 elevation)diabetics (GH elevations transiently reduce insulin sensitivity)competitive athletes (WADA prohibited)consider Sermorelin, which has a longer clinical history, as an alternative for adult GH optimisation goals

Frequently asked questions

How does ipamorelin differ from GHRP-6?

Both are GHS-R1a agonists, but the hormonal selectivity profiles differ substantially. GHRP-6 produces significant co-elevation of ACTH, cortisol, and appetite-stimulating ghrelin-like effects alongside GH release. Ipamorelin, as established in the 1998 Raun characterisation, does not meaningfully raise cortisol, ACTH, or prolactin at GH-releasing doses. In practical terms, GHRP-6 causes significant hunger and cortisol elevation; ipamorelin does not. This makes ipamorelin the preferable choice for most body composition and recovery protocols where cortisol elevation would be counterproductive.

How does ipamorelin differ from Sermorelin?

They work at different receptors through different pathways. Sermorelin is a GHRH analog — it acts at the GHRH receptor and mimics the natural hypothalamic signal that causes GH release. Ipamorelin acts at the GHS-R1a (ghrelin receptor), a separate pathway that is partially independent of somatostatin-mediated suppression. Sermorelin was FDA-approved (as Geref) and has a longer clinical track record. Ipamorelin acetate is on the FDA's Category 2 list for 503B outsourcing facilities, so US access through pharmacies varies. The two peptides are commonly stacked because their complementary receptor pathways produce synergistic GH release.

What is the CJC-1295 and ipamorelin stack?

CJC-1295 is a GHRH analog (modified GHRH 1-29) that acts at the GHRH receptor on the pituitary somatotroph cell — a different receptor from ipamorelin's GHS-R1a target. The two receptors have separate intracellular signalling pathways that, when activated simultaneously, produce greater GH release than either compound alone. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of approximately 30 minutes and is timed with ipamorelin for a combined pulse. CJC-1295 with DAC has a much longer half-life and is administered on a different schedule.

Can ipamorelin be obtained legally in the United States?

It is not FDA-approved, and its status depends on how it is supplied. Since September 2023 ipamorelin acetate has been on the FDA's Category 2 list (substances with significant safety concerns) for 503B outsourcing facilities. The FDA's table does not list it for 503A pharmacies, but it is not on the 503A bulks list either, so whether a given pharmacy will compound it varies — ask your pharmacist. It is not a scheduled controlled substance and possession is not typically criminalised, but WADA prohibits it. Sermorelin and tesamorelin, covered in separate profiles, have longer clinical histories.

Why does ipamorelin work better with CJC-1295 than alone?

The two peptides activate complementary intracellular pathways in the pituitary somatotroph cell. Ipamorelin activates GHS-R1a via the Gq/phospholipase C pathway. CJC-1295 activates GHRH-R via the Gs/adenylyl cyclase/cAMP pathway. When both pathways are activated simultaneously, they produce a supra-additive GH release — significantly greater than either compound alone. This synergy is the mechanistic basis for the stack's popularity and has been demonstrated in preclinical models.